Social: In contrast to factors in this analysis there is not much to say here besides already pointed out in the introduction of increasing ageing of the population in the Western world and increasing global population growth. For example according to World Bank in 2050 there is projected to be about 2 billion more people than now, and we have reached 7 billion people in 2011. The reason that no other important measurable social factors exist is that the company’s current product portfolio consists of treating hereditary diseases from Huntington’s dieses to Schizophrenia, together with treating diseases mostly associated with elderly people like Alzheimer’s and Parkinson’s disease, where social and cultural factors as a lifestyle have no impact on. One can argue that depression is dependent on social factors like not being satisfied with the current life, loneliness, stress or other lifestyle factors. However it is very hard to measure and therefore is not included in the analysis. Technological: The relevance of this factor cannot be underestimated in the of how immense it is in the pharmaceutical industry to introduce new drugs and new patents, especially in the branded part of the market. In very few words it represents competitive advantage and future business survival for Lundbeck as they as well on their homepage point out: The rise in R&D research and development is the basis for our future”. “..innovative expenditures relative to revenue from past four years speaks for itself how innovation is important for the company; from 19.60 % in 2007 to 25.80%, 23.20% and 20.60% in 2008, 2009 and 2010 respectively. More to the point Lundbeck has currently 9 drugs in development in their pipeline. The investments in R&D is not the only technological factor important for Lundbeck as a middle sized company, it is also important to work in collaborations with other pharmaceutical companies in research & development of new drugs for faster market introduction rates of the new drugs and more economical process, which stands for new research initiatives and a new ways of business. This is evident in Lundbeck’s seven current R&D collaborations: 1. Takeda Pharmaceutical Company Limited, 2. Genmab A/S, 3. Kyowa Hakko Kirin Co., Ltd., 4. Biotie Besides presenting the Therapies Corp. 5. Paion AG, 6. Zenobia Therapies, Inc. and 7. Vernalis plc.
Social: In contrast to factors in this analysis there is not much to say here besides already pointed out in the introduction of increasing ageing of the population in the Western world and increasing global population growth. For example according to World Bank in 2050 there is projected to be about 2 billion more people than now, and we have reached 7 billion people in 2011. The reason that no other important measurable social factors exist is that the company’s current product portfolio consists of treating hereditary diseases from Huntington’s dieses to Schizophrenia, together with treating diseases mostly associated with elderly people like Alzheimer’s and Parkinson’s disease, where social and cultural factors as a lifestyle have no impact on. One can argue that depression is dependent on social factors like not being satisfied with the current life, loneliness, stress or other lifestyle factors. However it is very hard to measure and therefore is not included in the analysis. Technological: The relevance of this factor cannot be underestimated in the of how immense it is in the pharmaceutical industry to introduce new drugs and new patents, especially in the branded part of the market. In very few words it represents competitive advantage and future business survival for Lundbeck as they as well on their homepage point out: “..innovative research and development is the basis for our future”. The rise in R&D expenditures relative to revenue from past four years speaks for itself how innovation is important for the company; from 19.60 % in 2007 to 25.80%, 23.20% and 20.60% in 2008, 2009 and 2010 respectively. More to the point Lundbeck has currently 9 drugs in development in their pipeline. The investments in R&D is not the only technological factor important for Lundbeck as a middle sized company, it is also important to work in collaborations with other pharmaceutical companies in research & development of new drugs for faster market introduction rates of the new drugs and more economical process, which stands for new research initiatives and a new ways of business. This is evident in Lundbeck’s seven current R&D collaborations: 1. Takeda Pharmaceutical Company Limited, 2. Genmab A/S, 3. Kyowa Hakko Kirin Co., Ltd., 4. Biotie Therapies Corp. 5. Paion AG, 6. Zenobia Therapies, Inc. and 7. Vernalis plc. Besides presenting the
SpecialeLundbeckIndhold.docx